Skip to Main Content
Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. Although it may feel like a holiday season to some, the parade of new developments has not slowed, not even a wee bit. And so, we are marching to the Pharmalot cafeteria for still another cup of stimulation since our neurons need all the help they can get. Our choice today is maple bourbon. Feel free to join us. Meanwhile, as always, we have assembled a few items of interest as you begin your own journey. We hope all goes well today and that you are productive, as ever. And of course, do keep in touch. We always appreciate your postcards and telegrams…

Moderna (MRNA) disclosed that a booster shot of its coronavirus vaccine significantly raises the level of antibodies that can thwart the Omicron variant, The New York Times writes. The results show the currently authorized booster dose of 50 micrograms — half the dose given for primary immunization — increased the level of antibodies by roughly 37-fold. A full dose of 100 micrograms was even more powerful, raising antibody levels about 83-fold compared with pre-boost levels. The results are based on laboratory tests that do not capture the full range of the body’s immune response against the virus. The data have also not been published or reviewed by independent experts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment